Magazine article Nutrition Health Review

Spare Node-Negative Cancer Patients Complex Therapy

Magazine article Nutrition Health Review

Spare Node-Negative Cancer Patients Complex Therapy

Article excerpt

More than one-third of breast cancer patients with negative axillary nodes (NAN) can be spared routine adjuvant therapy, according to new research by an expert from the Breast Evaluation Center at the State University of New York at Buffalo School of Medicine.

This finding may put to rest the widespread belief that all NAN patients should receive routine systemic adjuvant chemotherapy or hormonal therapy, Professor Dr. Dutzu Rosner, Coordinator of the Breast Evaluation Center, has declared.

"NAN patients represent a heterogeneous population in terms of risk and prognosis, and should not be treated as if they were all the same," said Professor Rosner. Rosner has identified four subjects of patients who have an excellent chance of recovery using surgery alone and who should be spared routine administration of systemic adjuvant therapy.

In May 1988, the National Cancer Institute issued a clinical alert calling for the routine use of systemic adjuvant therapy for all NAN breast cancers, an endorsement that has fomented a passionate debate around the United States on the risks, benefits and cost-effectiveness of such treatment.

Rosner believes it makes more sense to identify subjects of low-risk, good prognosis NAN breast cancer patients who could be spared the agony and financial cost of unnecessary additional treatment. "During the past few years we have accelerated our efforts to isolate those NAN breast cancer patients who would most likely benefit from adjuvant systemic therapy from those who might be spared," he said. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.